信号通路通过SOX2上调作为肿瘤细胞顺铂耐药的关键调控因子。

IF 3.5 4区 医学 Q2 ONCOLOGY
Negin Taghehchian, Iman Akhlaghipour, Amir Sadra Zangouei, Mahsa Palizkaran Yazdi, Meysam Moghbeli
{"title":"信号通路通过SOX2上调作为肿瘤细胞顺铂耐药的关键调控因子。","authors":"Negin Taghehchian, Iman Akhlaghipour, Amir Sadra Zangouei, Mahsa Palizkaran Yazdi, Meysam Moghbeli","doi":"10.1007/s12032-025-03004-9","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy is one of the first-line treatment options in cancer patients. Cisplatin (CDDP) is widely used as one of the antineoplastic agents in many cancers. Nevertheless, CDDP resistance is considered as a therapeutic challenge in cancer. Considering the CDDP side effects in normal tissues, prediction of CDDP response helps to select a suitable therapeutic strategy in cancer patients. Sex-determining region Y-box 2 (SOX2) is a critical regulator of tumor growth and embryogenesis that is involved in tumor metastasis, apoptosis, and cell proliferation, through association with other developmental/oncogenic signaling pathways. SOX2 has also a crucial role in CDDP resistance in tumor cells. Therefore, we discussed the role of SOX2 in regulation of CDDP response in tumor cells. It has been reported that SOX2 upregulation through PI3K/AKT, WNT, Hippo, and TGF-β signaling pathways mainly promotes the CDDP resistance in tumor cells. The present review can be an effective step in introducing SOX2 as a prognostic marker as well as a therapeutic target in cancer patients.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"437"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Signaling pathways as the pivotal regulators of cisplatin resistance in tumor cells through SOX2 upregulation.\",\"authors\":\"Negin Taghehchian, Iman Akhlaghipour, Amir Sadra Zangouei, Mahsa Palizkaran Yazdi, Meysam Moghbeli\",\"doi\":\"10.1007/s12032-025-03004-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chemotherapy is one of the first-line treatment options in cancer patients. Cisplatin (CDDP) is widely used as one of the antineoplastic agents in many cancers. Nevertheless, CDDP resistance is considered as a therapeutic challenge in cancer. Considering the CDDP side effects in normal tissues, prediction of CDDP response helps to select a suitable therapeutic strategy in cancer patients. Sex-determining region Y-box 2 (SOX2) is a critical regulator of tumor growth and embryogenesis that is involved in tumor metastasis, apoptosis, and cell proliferation, through association with other developmental/oncogenic signaling pathways. SOX2 has also a crucial role in CDDP resistance in tumor cells. Therefore, we discussed the role of SOX2 in regulation of CDDP response in tumor cells. It has been reported that SOX2 upregulation through PI3K/AKT, WNT, Hippo, and TGF-β signaling pathways mainly promotes the CDDP resistance in tumor cells. The present review can be an effective step in introducing SOX2 as a prognostic marker as well as a therapeutic target in cancer patients.</p>\",\"PeriodicalId\":18433,\"journal\":{\"name\":\"Medical Oncology\",\"volume\":\"42 10\",\"pages\":\"437\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12032-025-03004-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-025-03004-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

化疗是癌症患者的一线治疗选择之一。顺铂(CDDP)作为一种抗肿瘤药物被广泛应用于多种癌症。然而,CDDP耐药性被认为是癌症治疗中的一个挑战。考虑到CDDP在正常组织中的副作用,预测CDDP反应有助于癌症患者选择合适的治疗策略。性别决定区Y-box 2 (SOX2)是肿瘤生长和胚胎发生的关键调控因子,通过与其他发育/致癌信号通路相关,参与肿瘤转移、细胞凋亡和细胞增殖。SOX2在肿瘤细胞的CDDP耐药中也起着至关重要的作用。因此,我们讨论SOX2在肿瘤细胞中调控CDDP应答中的作用。有报道称,SOX2通过PI3K/AKT、WNT、Hippo、TGF-β等信号通路上调,主要促进肿瘤细胞对CDDP的耐药。目前的综述可以作为引入SOX2作为癌症患者预后标志物和治疗靶点的有效步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Signaling pathways as the pivotal regulators of cisplatin resistance in tumor cells through SOX2 upregulation.

Chemotherapy is one of the first-line treatment options in cancer patients. Cisplatin (CDDP) is widely used as one of the antineoplastic agents in many cancers. Nevertheless, CDDP resistance is considered as a therapeutic challenge in cancer. Considering the CDDP side effects in normal tissues, prediction of CDDP response helps to select a suitable therapeutic strategy in cancer patients. Sex-determining region Y-box 2 (SOX2) is a critical regulator of tumor growth and embryogenesis that is involved in tumor metastasis, apoptosis, and cell proliferation, through association with other developmental/oncogenic signaling pathways. SOX2 has also a crucial role in CDDP resistance in tumor cells. Therefore, we discussed the role of SOX2 in regulation of CDDP response in tumor cells. It has been reported that SOX2 upregulation through PI3K/AKT, WNT, Hippo, and TGF-β signaling pathways mainly promotes the CDDP resistance in tumor cells. The present review can be an effective step in introducing SOX2 as a prognostic marker as well as a therapeutic target in cancer patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Oncology
Medical Oncology 医学-肿瘤学
CiteScore
4.20
自引率
2.90%
发文量
259
审稿时长
1.4 months
期刊介绍: Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信